

Merck KGaA, Darmstadt, Germany Pipeline

September 25, 2017

Phase I

M2698
p70S6K & Akt inhibitor
Solid tumors

M3814
DNA-PK inhibitor
Solid tumors

M9831 (VX-984)
DNA-PK inhibitor
Solid tumors

M6620 (VX-970)
ATR inhibitor
Solid tumors

M4344 (VX-803)
ATR inhibitor
Solid tumors

M7583
BTK inhibitor
Hematological malignancies

avelumab
anti-PD-L1 mAb
Solid tumors

avelumab
anti-PD-L1 mAb
Hematological malignancies

M9241 (NHS-IL12)⁴
Cancer immunotherapy
Solid tumors

M7824
anti-PD-L1/TGFbeta trap
Solid tumors

M1095 (ALX-0761)⁵
anti-IL-17 A/F nanobody
Psoriasis

Phase II

tepotinib
c-Met kinase inhibitor
Non-small cell lung cancer

tepotinib
c-Met kinase inhibitor
Hepatocellular cancer

avelumab - anti-PD-L1 mAb
Merkel cell cancer 1L¹

sprifermin
fibroblast growth factor 18
Osteoarthritis

atacept
anti-Blys/anti-APRIL fusion protein
Systemic lupus erythematosus

atacept
anti-Blys/anti-APRIL fusion protein
IgA nephropathy

abrituzumab
anti-CD51 mAb
Systemic sclerosis with interstitial lung disease

evobrutinib
BTK inhibitor
Rheumatoid arthritis

evobrutinib
BTK inhibitor
Systemic lupus erythematosus

evobrutinib
BTK inhibitor
Multiple sclerosis

Phase III

avelumab - anti-PD-L1 mAb
Non-small cell lung cancer 1L¹

avelumab - anti-PD-L1 mAb
Non-small cell lung cancer 2L²

avelumab - anti-PD-L1 mAb
Gastric cancer 1L-M^{1M}

avelumab - anti-PD-L1 mAb
Gastric cancer 3L³

avelumab - anti-PD-L1 mAb
Ovarian cancer platinum resistant/refractory

avelumab - anti-PD-L1 mAb
Ovarian cancer 1L¹

avelumab - anti-PD-L1 mAb
Urothelial cancer 1L-M^{1M}

avelumab - anti-PD-L1 mAb
Renal cell cancer 1L¹

avelumab - anti-PD-L1 mAb
Locally advanced head and neck cancer

■ Neurology

■ Oncology

■ Immunology

■ Immuno-Oncology

¹ First Line treatment; ^{1M} First Line maintenance treatment; ² Second Line treatment; ³ Third Line treatment.

⁴ Sponsored by the National Cancer Institute (USA).

⁵ As announced on March 30, 2017, in an agreement with Avillion, anti-IL-17 A/F nanobody will be developed by Avillion for plaque psoriasis and commercialized by Merck KGaA, Darmstadt, Germany.